Semaglutide is a new diabetes drug with multiple therapeutic benefits, with impressive performance in lowering blood sugar, reducing weight and improving cardiovascular health. However, patients still need to pay attention to possible side effects during use and use the medication rationally under the guidance of a doctor.

Tirzepatide, an innovative dual receptor agonist, has shown great potential in the treatment of obesity and diabetes. Its significant weight loss effect and good market performance make it one of the high-profile drugs in this field. However, patients should also pay attention to possible adverse reactions and contraindications when using it, and use it rationally under the guidance of a doctor.

According to clinical trial data, various doses of retatrutide treatment showed clinically significant weight loss, with greater weight loss in women.
In addition, retatrutide significantly improved all lipid levels except HDL and had significant benefits on patients' diastolic and systolic blood pressure.
Retatrutide, as a new multiple receptor agonist drug, shows great potential in the treatment of obesity and NAFLD/NASH. As clinical trials progress, it is expected to become one of the important drugs in the treatment of these diseases.